Table 2.
Characteristics of patients in set 2 (test set) and platform used for analysis
| Infection, patient no. | Age, y | Ethnicity | Sex | Clinical disease | Analysis | Platform | Antimicrobial therapy | |
|---|---|---|---|---|---|---|---|---|
| Influenza | ||||||||
| 311 | 0.1 | Hispanic | M | Influenza B, fever, URI | Fig. 6C | Illumina Sentrix Hu6 | Ampicillin + ceftriaxone | |
| 320 | 0.04 | Hispanic | F | Influenza B, fever, URI | Fig. 6C | Illumina Sentrix Hu6 | Ampicillin + gentamicin | |
| 517 | 0.5 | Hispanic | F | Influenza A, pneumonia | Fig. 6A-B | Affymetrix U133plus2 | None | |
| 519 | 0.13 | Hispanic | F | Influenza A, fever | Fig. 6C | Illumina Sentrix Hu6 | None | |
| 524 | 6 | Hispanic | M | Influenza A, fever | Fig. 6A | Affymetrix U133plus2 | None | |
| 527 | 0.13 | Black | M | Influenza A, fever | Fig. 6C | Illumina Sentrix Hu6 | Ampicillin + ceftriaxone | |
| 530 | 0.38 | Hispanic | M | Influenza A, fever, seizure | Fig. 6C | Illumina Sentrix Hu6 | None | |
| 532 | 0.08 | Hispanic | F | Influenza A, fever, cough | Fig. 6A-B | Affymetrix U133plus2 | Ampicillin + gentamicin | |
| 533 | 11 | White | M | Influenza B, fever, cough | Fig. 6A-B | Affymetrix U133plus2 | None | |
| 536 | 2 | Hispanic | F | Influenza A, fever, cough | Fig. 6A-B | Affymetrix U133plus2 | None | |
| 540 | 0.08 | Hispanic | M | Influenza A, fever, cough | Fig. 6A-B | Affymetrix U133plus2 | Ampicillin + gentamicin | |
| 542 | 0.04 | Hispanic | F | Influenza A, fever | Fig. 6C | Illumina Sentrix Hu6 | Ampicillin + gentamicin | |
| 547 | 1.33 | Black | F | Influenza A, encephalitis | Fig. 6A | Affymetrix U133plus2 | Ceftriaxone + oseltamivir | |
| 549 | 13 | Hispanic | F | Influenza B fever, syncope | Fig. 6A | Affymetrix U133plus2 | Ceftriaxone + vancomycin + oseltamivir | |
| 553 | 1.5 | White | F | Influenza A fever, URI | Fig. 6A-B | Affymetrix U133plus2 | Oseltamivir | |
| 556 | 3.5 | White | F | Influenza A fever, seizure | Fig. 6C | Illumina Sentrix Hu6 | Ceftriaxone + oseltamivir | |
| 560 | 10 | Black | F | Influenza B, encephalitis | Fig. 6C | Illumina Sentrix Hu6 | Acyclovir | |
| 567 | 2 | Hispanic | F | Influenza B, fever, URI | Fig. 6A-B | Affymetrix U133plus2 | None | |
| S aureus | ||||||||
| 305 | 4.5 | Hispanic | F | MSSA, bacteremia, suppurative arthritis, osteomyelitis | Fig. 6A | Affymetrix U133plus2 | Cefazolin | |
| 308 | 12 | Black | F | MSSA, disseminated with pneumonia | Fig. 6A-B | Affymetrix U133plus2 | Oxacillin + clindamycin | |
| 369 | 14 | Black | M | MRSA disseminated | Fig. 6A | Affymetrix U133plus2 | Vancomycin, rifampin | |
| 372 | 14 | White | M | MRSA, bacteremia, osteomyelitis | Fig. 6A | Affymetrix U133plus2 | Vancomycin, rifampin | |
| 374 | 1.75 | Black | M | MRSA bacteremia, suppurative arthritis | Fig. 6A | Affymetrix U133plus2 | Vancomycin | |
| 380 | 7.5 | Black | M | MRSA osteomyelitis, suppurative arthritis | Fig. 6A | Affymetrix U133plus2 | Clindamycin | |
| 458 | 12 | Black | M | MRSA disseminated | Fig. 6C | Illumina Sentrix Hu6 | Vancomycin + rifampin + linezolid | |
| 459 | 10 | White | F | MSSA osteomyelitis, suppurative arthritis | Fig. 6C | Illumina Sentrix Hu6 | Oxacillin + rifampin | |
| 465 | 13 | White | M | MRSA, osteomyelitis, suppurative arthritis, bacteremia | Fig. 6C | Illumina Sentrix Hu6 | Vancomycin | |
| 466 | 0.5 | Black | M | MRSA, SST abscess | Fig. 6C | Illumina Sentrix Hu6 | Clindamycin | |
| 472 | 0.08 | White | M | MSSA, SST abscess | Fig. 6C | Illumina Sentrix Hu6 | Cefazolin | |
| 475 | 1.33 | Black | M | MSSA, suppurative arthritis | Fig. 6C | Illumina Sentrix Hu6 | Nafcillin | |
| 477 | 6 | Black | M | MRSA, bacteremia, suppurative arthritis | Fig. 6C | Illumina Sentrix Hu6 | Clindamycin + rifampin | |
| 480 | 12 | White | M | MSSA, bacteremia | Fig. 6C | Illumina Sentrix Hu6 | Clindamycin + doxycycline | |
| 489 | 1.08 | White | M | MRSA, SST abscess | Fig. 6C | Illumina Sentrix Hu6 | Clindamycin | |
| 522 | 9.5 | Black | F | MRSA, bacteremia, osteomyelitis | Fig. 6C | Illumina Sentrix Hu6 | Vancomycin + rifampin | |
| 529 | 1.75 | Black | M | MRSA bacteremia, pneumonia | Fig. 6C | Illumina Sentrix Hu6 | Vancomycin + rifampin | |
| 535 | 0.58 | Other | F | MSSA, suppurative arthritis | Fig. 6C | Illumina Sentrix Hu6 | Cefazolin | |
| 537 | 9 | Black | F | MSSA, bacteremia, osteomyelitis, suppurative arthritis | Fig. 6C | Illumina Sentrix Hu6 | Oxacillin | |
| S pneumoniae | ||||||||
| 96 | 1.33 | Hispanic | M | Pneumonia, empyema | Fig. 6A-B | Affymetrix U133plus2 | Ceftriaxone + azithromycin | |
| 265 | 2 | White | F | Pneumonia, empyema | Fig. 6A-B | Affymetrix U133plus2 | Ceftriaxone + vancomycin | |
| 268 | 3 | Hispanic | M | Pneumonia, empyema | Fig. 6A-B | Affymetrix U133plus2 | Ceftriaxone + clindamycin | |
| 277 | 16 | White | M | Pneumonia, empyema | Fig. 6A-B | Affymetrix U133plus2 | Vancomycin + ceftriaxone | |
| 287 | 3 | White | F | Pneumonia, bacteremia | Fig. 6A-B | Affymetrix U133plus2 | Vancomycin + ceftriaxone | |
| 289 | 2 | Hispanic | M | Pneumonia, empyema | Fig. 6A-B | Affymetrix U133plus2 | Vancomycin + ceftriaxone | |
| 471 | 2 | White | F | Bacteremia, meningitis | Fig. 6C | Illumina Sentrix Hu6 | Vancomycin + ceftriaxone | |
| 473 | 2.5 | Hispanic | M | Bacteremia, pneumonia | Fig. 6C | Illumina Sentrix Hu6 | Ceftriaxone | |
| 523 | 3 | Hispanic | M | Suppurative arthritis | Fig. 6C | Illumina Sentrix Hu6 | Cefazolin | |
For influenza (n = 18), median age, 11 months (range, 2 week to 13 years); S aureus (n = 19), median age, 7.5 years (range, 0.08 to 14 years); and S pneumoniae (n = 9), median age, 2.5 years (range, 1.3-16 years).
MSSA indicates methicillin-susceptible S aureus; MRSA, methicillin-resistant S aureus; and SST, skin/soft tissue infection.